RAF inhibitors combined with asciminib can treat acute myeloid leukemia (AML) with BCR-ABL-TKI resistance.113 The ERK inhibitor, ulixertinib, combined with dasatinib synergistically expedited NB cell death.114 Furthermore, the combination of MEK inhibitors and TKIs receives the most attention. The gene discussed is BCR; the disease is acute myeloid leukemia.